Zai Lab

Zai Lab is an innovative biopharmaceutical company based in China and the U.S., focused on delivering transformational outcomes to patients around the world.

[Zai Lab @ZaiLab_Global]

This weekend, we're at #ASCO26, highlighting the ongoing trial evaluating our investigational treatment for small-cell lung cancer. Read more here: https://t.co/oCCBtyiPjl

[Zai Lab @ZaiLab_Global]

#Breaking: The U.S. FDA granted Fast Track designation to our experimental targeted antibody-drug conjugate for extrapulmonary neuroendocrine carcinomas. Learn more about this milestone: https://t.co/NH1uJASlZl

[Zai Lab @ZaiLab_Global]

Today, we shared Q1 earnings results and notable commercial updates. Read our full earnings announcement:
https://t.co/VL0jc6CEmj

[Zai Lab @ZaiLab_Global]

#NEWS: Dr. Thummalapalli speaks to @ecancer about early-phase results evaluating zoci, a novel DLL3-targeting antibody-drug conjugate, in patients with advanced neuroendocrine carcinomas who have progressed after platinum-based chemotherapy. @rohit_thum https://t.co/pumCHJaK7P

[Zai Lab @ZaiLab_Global]

#Breaking at #AAI2026: We're sharing positive preclinical study results from our investigational bispecific antibody in atopic dermatitis and other disease models. Learn more: https://t.co/5UZ4XUu0Vd

[Zai Lab @ZaiLab_Global]

At #AACR26, we will present data demonstrating the progress of our #oncology pipeline, including important new data for our investigational treatment for people with small-cell lung cancer. Learn more: https://t.co/LzMpqVvHac

[Zai Lab @ZaiLab_Global]

#NEWS: We announced a clinical collaboration with @Boehringer to pioneer a potential dual DLL3-targeting investigational combination for small-cell lung cancer and other neuroendocrine carcinomas.

Learn more: https://t.co/KUfJpD2br9 #SLC #Innovation #Oncology

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab announces global clinical trial collaboration and supply agreement with @Amgen

Learn more: https://t.co/Af27FUJxre

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab will present new data on three internally developed oncology candidates at #AACR26, including zoci (DLL3 ADC), ZL‑6201 (LRRC15 ADC), and ZL‑1222 (PD‑1/IL‑12).

Learn more: https://t.co/CSLtjhXQUK #ADC #Oncology #Immunotherapy

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab announces fourth quarter and full-year 2025 financial results along with recent product highlights and corporate updates.

Learn more about our pipeline progress and healthcare innovation: https://t.co/rygJwdik7C

#earnings #financialresults #oncology #ADC

[Zai Lab @ZaiLab_Global]

Celebrating five years of partnership with @argenxglobal. Together, we’ve accelerated development, expanded patient access, and supported thousands across China—including those living with gMG and CIDP. Grateful for our teams driving impact and innovation forward. #LifeSciences

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco today @ 3PM PT / 6PM ET. Learn more about our 2026 strategic priorities and global pipeline progress: https://t.co/bKMfKzmpZp
#JPM26 #Innovation #ADC #oncology

[Zai Lab @ZaiLab_Global]

@LMatuson71920 Thanks for your note, we will send you a direct message.

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab dosed the first participant in our Global Phase 1/1b study of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis. Discover the potential of ZL-1503: https://t.co/6qnfYTdGuQ

[Zai Lab @ZaiLab_Global]

Zai Lab's President and COO Josh Smiley spoke at @FinancialTimes Global Pharma and Biotech Summit in London today on a panel discussing China's transformation into a biopharma innovation powerhouse.

#FTPharma #Innovation #Biotech #BioPharma

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab announces third quarter 2025 financial results along with recent product highlights and corporate updates.
Learn more about our pipeline progress and healthcare innovation: https://t.co/CXJsAYDaWn
#earnings #financialresults #oncology #ADC #healthcare #innovation

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab announces updated data from the global Ph1 clinical trial of zocilurtatug pelitecan (zoci)—formerly ZL-1310— today at the AACR-NCI-EORTC International Conference. Learn more about the initiation of our global Ph3 Registrational Study: https://t.co/uHphQ512JV

#ADC

[Zai Lab @ZaiLab_Global]

#NEWS: Zai Lab will deliver an oral presentation featuring updated data from our global Phase 1 trial of zocilurtatug pelitecan (ZL-1310) at the upcoming 2025 AACR-NCI-EORTC Conference in Boston. Visit: https://t.co/guOksRR36H

#ESSCLC #DLL3 #ADC #Targets25 #LungCancer

[Zai Lab @ZaiLab_Global]

Join us in recognizing #WorldMentalHealthDay.

At Zai Lab, we stand with the global community in raising awareness and reducing stigma around mental health.

Join the movement to advocate for mental health worldwide: https://t.co/MbFYgR9WmK

[Zai Lab @ZaiLab_Global]

This #WorldLungDay, Zai Lab reaffirms its commitment to advancing awareness of lung health and the global impact of lung diseases, including lung cancer.

Join the global movement to protect, promote, and prioritize lung health: https://t.co/GH3SABsHNP